Ventana Medical Systems have signed biotech deals to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.
As part of the biotech deals agreement, Ventana will utilize its immunohistochemistry technology platform, experience and expertise in companion diagnostic development and premarket approval (PMA) submissions to support Boehringer Ingelheim's personalized medicine healthcare strategies for cancer drug development.
For further deal information visit Current Agreements (subscription required)
Read: more on Boehringer Ingelheim company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with Boehringer Ingelheim
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity